Next Article in Journal
Do Antibiotics Potentiate Proteases in Hemotoxic Snake Venoms?
Next Article in Special Issue
Cnf1 Variants Endowed with the Ability to Cross the Blood–Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma
Previous Article in Journal
Toxicity of Carlina Oxide—A Natural Polyacetylene from the Carlina acaulis Roots—In Vitro and in Vivo Study
Previous Article in Special Issue
Botulinum Neurotoxins and Cancer—A Review of the Literature
Review

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 11 March 2020 / Revised: 7 April 2020 / Accepted: 7 April 2020 / Published: 9 April 2020
(This article belongs to the Special Issue Toxins and Cancer Therapy)
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit these potent immunological processes in the fight against cancer has been a longstanding effort dating back over 100 years to when Dr. William Coley purposefully infected cancer patients with a cocktail of heat-killed bacteria to stimulate anti-cancer immune processes. Although the field of cancer immunotherapy has been dotted with skepticism at times, the success of immune checkpoint inhibitors and recent FDA approvals of autologous cell therapies have pivoted immunotherapy to center stage as one of the most promising strategies to treat cancer. This review aims to summarize historic milestones throughout the field of cancer immunotherapy as well as highlight current and promising immunotherapies in development. View Full-Text
Keywords: cancer; immunotherapy; vaccine; immune checkpoint inhibitors; adoptive cell therapy; cytokine therapy; Coley’s Toxins cancer; immunotherapy; vaccine; immune checkpoint inhibitors; adoptive cell therapy; cytokine therapy; Coley’s Toxins
Show Figures

Figure 1

MDPI and ACS Style

Carlson, R.D.; Flickinger, J.C., Jr.; Snook, A.E. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins 2020, 12, 241. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040241

AMA Style

Carlson RD, Flickinger JC Jr., Snook AE. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins. 2020; 12(4):241. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040241

Chicago/Turabian Style

Carlson, Robert D., John C. Flickinger Jr., and Adam E. Snook 2020. "Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy" Toxins 12, no. 4: 241. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040241

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop